Navigation Links
Carl Zeiss Continues on Track to Further Growth and Investment
Date:12/13/2012

STUTTGART, Germany, December 13, 2012 /PRNewswire/ --

Strong Portfolio Offsets Cyclical Fluctuations in the Semiconductor Manufacturing Technology Business Group

The Carl Zeiss Group ended fiscal year 2011/12 with a two percent increase in revenue to a total of EUR 4.163 billion (prior year*: EUR 4.084 billion). EBIT totaled EUR 420 million (prior year*: EUR 608 million). "2011/12 was a very successful fiscal year for Carl Zeiss. "We have surpassed the figure we forecast last year: revenue is slightly above the equivalent total in the prior year," said Dr. Michael Kaschke, President and CEO of Carl Zeiss. "What is particularly notable is that our strong portfolio has enabled us to successfully offset the cyclical downturn in the revenue of the Semiconductor Manufacturing Technology business group. This would not have been possible just a few years ago."  

In 2011/12 Carl Zeiss hired 900 new recruits worldwide and increased its investments in research and development by 14 percent. Investments in property, plant and equipment totaled EUR 289 million, allowing the company to modernize and expand its global infrastructure.

*Calculated on a like-for-like basis

More information at http://www.zeiss.de/press

Carl Zeiss

The Carl Zeiss Group is an international leader in the fields of optics and optoelectronics. In fiscal year 2011/12 the company's approx. 24,000 employees generated revenue of about 4.163 billion euros. In the markets for Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics, Carl Zeiss has contributed to technological progress all over the world for more than 160 years.

The Carl Zeiss Group develops and produces planetariums, eyeglass lenses, camera and cine lenses and binoculars as well as solutions for biomedical research, medical technology and the semiconductor, automotive and mechanical engineering industries. Carl Zeiss is present in over 40 countries around the globe with about 40 production sites, over 50 sales and service locations and approximately 20 research and development centers. Carl Zeiss AG is fully owned by the Carl Zeiss Stiftung (Carl Zeiss Foundation). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany.

Press contact
Jörg Nitschke, Carl Zeiss, Konzernkommunikation, Pressesprecher,
Phone +49(0)7364 20-3242, Email: joerg.nitschke@zeiss.com



'/>"/>
SOURCE Carl Zeiss AG
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accelr8 to Hold 2012 Annual Meeting of Shareholders; Product Development Continues with Launch Expected in 2015
2. FUJIFILM Continues To Build 3D Digital Roadmap To Womans Imaging
3. Fujifilm Continues To Grow Its Family Of DR Portables
4. Isis To Receive $1.25 Million Payment As Pfizer Continues Development Of EXC 001
5. Philips continues to improve access to treatment for common cause of death in the U.S. with the delivery of its one-millionth AED
6. PathGroup Unveils a New Look; Continues to Expand Footprint
7. Brainlab Continues to Advance Global Treatment Access and Consistency in Cancer Care Centers
8. Medisafe 1 Technologies Corp has of Today Acquired 3,100,000 Shares and Continues to Acquire Shares Under its $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share to Facilitate its On-going Acquisitions Activity Plan
9. Top OTC Brand deploys Semantelli AETracker to monitor Adverse Events in Facebook
10. Novo Nordisk introduces HemaGo, a mobile application to track hemophilia treatment, bleeding episodes and life events
11. FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):